Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
Mike Havrilla is a clinical IV pharmacist, marathon runner, writer and biotech stock trader with experience that includes being a licensed pharmacist since January 2004, online investing since August 1997 and writing for investors since April 2007. Havrilla holds a doctorate in pharmacy and a bachelor's degree in biology from the University of Pittsburgh. He worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed 22 marathons. Havrilla merged his previous site with BioRunUp.com/Mark Messier in October 2010, resulting in a biotech stock research and trading subscription service. For more information, visit Havrilla's LinkedIn profile.
How a Professional Investor Uses Twitter to Trade Smarter: Mike Havrilla (7/2/13) Drug development is full of surprises, and those surprises are hitched to the catalysts that move biotech company stocks. Mike Havrilla, co-founder and analyst with BioRunUp, processes and trades on the news flow surrounding biotech and specialty pharma companies as they navigate the turbulent development cycle. In this interview with The Life Sciences Report, Havrilla talks about his methods and shares three rich ideas that could create doubles or triples for investors.
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >